Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism

This study has been completed.
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
Samuel Z.Goldhaber, MD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT00413374
First received: December 15, 2006
Last updated: April 27, 2012
Last verified: April 2012
Results First Received: June 22, 2011  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Deep Vein Thrombosis
Pulmonary Embolism
Intervention: Drug: Enoxaparin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Enoxaparin Recieved low molecular weight heparin (LMWH) as a "bridge" to warfarin

Participant Flow:   Overall Study
    Enoxaparin  
STARTED     40  
COMPLETED     34  
NOT COMPLETED     6  
Ineligible due to screening criteria.                 3  
Adverse Event                 1  
Lost to Follow-up                 1  
Surgery                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Enoxaparin Recieved low molecular weight heparin (LMWH) as a "bridge" to warfarin

Baseline Measures
    Enoxaparin  
Number of Participants  
[units: participants]
  40  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     35  
>=65 years     5  
Age  
[units: years]
Mean ± Standard Deviation
  47.95  ± 16.2  
Gender  
[units: participants]
 
Female     21  
Male     19  
Region of Enrollment  
[units: participants]
 
United States     40  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Major Bleeding Complication   [ Time Frame: 30 Days ]

2.  Primary:   Recurrent VTE   [ Time Frame: 30 Days ]

3.  Primary:   Death   [ Time Frame: 30 Days ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Research Coordinator
Organization: Brigham and Women's Hospital
phone: 617-732-6984
e-mail: arao2@partners.org


Publications:

Responsible Party: Samuel Z.Goldhaber, MD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT00413374     History of Changes
Other Study ID Numbers: 2006-P-000082
Study First Received: December 15, 2006
Results First Received: June 22, 2011
Last Updated: April 27, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board